India’s largest pharmaceutical firm, Sun Pharmaceutical is reportedly scouting for a partner to market 14 brands it acquired from Novartis in Japan. In April, a wholly-owned subsidiary of the company, acquired 14 established prescription brands from Novartis AG and Novartis Pharma AG in Japan, for $293 million.
The acquired brands will be marketed by a local marketing partner under the Sun label. The local marketing partner will also be responsible for distribution of the brands.
Sun Pharmaceutical is the world’s fifth largest specialty generic pharmaceutical company and India’s top pharmaceutical company. Its global presence is supported by 49 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: